“Doenças Sexualmente Transmissíveis: Algumas generalidades importantes”

José M. D. Poças

Diretor do SDI CHS HSB











I)- Introdução





A importância da visita médica



Samkange-Zeeb *et al. BMC Public Health* 2011, **11**:727
http://www.biomedcentral.com/1471-2458/11/727

BMC Public Health

RESEARCH ARTICLE Open Access

Awareness and knowledge of sexually transmitted diseases (STDs) among school-going adolescents in Europe: a systematic review of published literature

Florence N Samkange-Zeeb*, Lena Spallek and Hajo Zeeb

Abstract

Background: Sexually transmitted diseases (STDs) are a major health problem affecting mostly young people, not only in developing, but also in developed countries.
We conducted this systematic review to determine awareness and knowledge of school-going male and female adolescents in Europe of STDs and if possible, how they perceive their own risk of contracting an STD. Results of this review can help point out areas where STD risk communication for adolescents needs to be improved.

Methods: Using various combinations of the terms "STD", "HIV", "HPV", "Chlamydia", "Syphilis", "Gonorrhoea", "herpes", "hepatitis B", "knowledge", "awareness", and "adolescents", we searched for literature published in the PubMed database from 01.01.1990 up to 31.12.2010. Studies were selected if they reported on the awareness and/or knowledge of one or more STD among school-attending adolescents in a European country and were published in English or German. Reference lists of selected publications were screened for further publications of interest. Information from included studies was systematically extracted and evaluated.

Results: A total of 15 studies were included in the review. All were cross-sectional surveys conducted among school-attending adolescents aged 13 to 20 years. Generally, awareness and knowledge varied among the adolescents depending on gender.
Six STDs were focussed on in the studies included in the review, with awareness and knowledge being assessed in depth mainly for HIV/AIDS and HPV, and to some extent for chlamydia. For syphilis, gonorrhoea and herpes only awareness was assessed. Awareness was generally high for HIV/AIDS (above 90%) and low for HPV (range 5.4%–66%). Despite knowing that use of condoms helps protect against contracting an STD, some adolescents still regard condoms primarily as an interim method of contraception before using the pill.

Conclusion: In general, the studies reported low levels of awareness and knowledge of sexually transmitted diseases, with the exception of HIV/AIDS. Although, as shown by some of the findings on condom use, knowledge does not always translate into behaviour change, adolescents' sex education is important for STD prevention, and the school setting plays an important role. Beyond HIV/AIDS, attention should be paid to infections such as chlamydia, gonorrhoea and syphilis.

As novas tecnologias e a sexualidade dos jovens…







Recomendações de vigilância periódica

STD Screening is Critical:

If you are sexually active, be sure to talk to your healthcare provider about STD testing and which tests may be right for you.

Women:

- If you are a sexually active woman younger than 25, or have risk factors such as new or multiple sex partners, you should request annual chlamydia and gonorrhea tests.
- If you are a pregnant woman, you should request syphilis, HIV, chlamydia, and hepatitis B tests early in your pregnancy. If you have new or multiple sex partners, you should also request gonorrhea testing early in pregnancy.

Gay and bisexual men:

- If you are a sexually active man who is gay, bisexual, or has sex with men, you should request tests for syphilis, chlamydia, gonorrhea, and HIV at least once a year. More frequent STD testing is recommended for men at high risk.

Sources:
1. CDC. Sexually Transmitted Diseases Treatment Guidelines, 2015. MMWR 2015 Jun 5; 64(RR-03);1-137).

CDC's STI Screening Recommendations:

If you are sexually active, be sure to talk to your healthcare provider about STI testing and which tests may be right for you.

- All adults and adolescents should be tested at least once for HIV.
- Annual chlamydia screening for all sexually active women age 25 and under, as well as older women with risk factors such as new or multiple sex partners.
- Yearly gonorrhea screening for at-risk sexually active women (e.g., those with new or multiple sex partners, and women who live in communities with a high burden of disease).
- Syphilis, HIV, chlamydia, and hepatitis B screening for all pregnant women, and gonorrhea screening for at-risk pregnant women at the first prenatal visit, to protect the health of mothers and their infants.
- Trichomoniasis screening should be conducted at least annually for all HIV-infected women.
- Screening at least once a year for syphilis, chlamydia, gonorrhea, and HIV for all sexually active gay men, bisexual men, and other men who have sex with men (MSM). MSM who have multiple or anonymous partners should be screened more frequently for STIs (e.g., at 3 to 6 month intervals). In addition, MSM who have sex in conjunction with illicit drug use (particularly methamphetamine use) or whose sex partners participate in these activities should be screened more frequently.

Novas Normas do CDC!



Novos aspetos





Epidemiologia nos EUA I



Epidemiologia nos EUA II

Snapshot: STDs in the United States, 2014

In 2014, increases were seen in all three nationally reported STDs. The approximately 1.4 million cases of chlamydia represent the highest number of annual cases of any condition ever reported to CDC. Substantial increases were also seen among reported cases of gonorrhea and syphilis. While young people and women are most severely affected by STDs, increasing rates among men contributed to the overall increase in 2014 across all diseases.

Chlamydia

- Cases reported in 2014: 1,441,789
- Rate per 100,000 people: 456.1; increase of 2.8% since 2013

Gonorrhea

- Cases reported in 2014: 350,062
- Rate per 100,000 people: 110.7; increase of 5.1% since 2013

Syphilis (primary and secondary)

- Cases reported in 2014: 19,999
- Rate per 100,000 people: 6.3; 15.1% increase since 2013

Syphilis (congenital)

- Cases reported in 2014: 458
- Rate per 100,000 live births: 11.6; 27.5% increase since 2013

CDC FACT SHEET

Incidence, Prevalence, and Cost of Sexually Transmitted Infections in the United States

CDC's estimates of sexually transmitted infections:

Annual new infections
(Incidence)

20 million

– United States, 2008

Total infections
(Prevalence)

110 million

– United States, 2008

Total medical costs

$16 billion

– United States (in 2010 dollars)

Implicações importantes das DTSs

STIs Facilitate HIV Transmission

- Disruption of epithelial/mucosal barriers
- Increase the number of HIV target cells in the genital tract
- Increase expression of HIV co-receptors
- Induce secretion of cytokines (increase HIV shedding)
- HIV alters natural history of some STIs



Fleming DT and Wasserheit JN. From Epidemiological Synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. *Sex Transm Inf* 1999;75:3-17.

Apresentação clínica

STDs of Concern

- "Sores" (ulcers)
  - Syphilis
  - Genital herpes (HSV-2, HSV-1)
  - Others uncommon in the U.S.
    - Lymphogranuloma venereum
    - Chancroid
    - Granuloma inguinale

Does It Hurt?

- Painful
  - Chancroid
  - Genital herpes simplex
- Painless
  - Syphilis
  - Lymphogranuloma venereum
  - Granuloma inguinale

STDs of Concern (continued)

- "Drips" (discharges)
  - Gonorrhea
  - Chlamydia
  - Nongonococcal urethritis / mucopurulent cervicitis
  - Trichomonas vaginitis / urethritis
  - Candidiasis (not an STD)
  - Bacterial vaginosis (sexually associated)

II)- Aspetos particulares das diversas doenças e respetivos agentes











Infeções por bactérias I: *Haemophilus ducrey* (Cancróide)

- Cocobacilo gram negativo anaeróbio
- > 20.000.000 casos / ano (mundo)
- Endémico: Asia, África, América Latina
- Período de incubação: 4 a 7 dias



Recommended Regimens
Azithromycin 1 g orally in a single dose OR **Ceftriaxone** 250 mg IM in a single dose OR **Ciprofloxacin** 500 mg orally twice a day for 3 days OR **Erythromycin** base 500 mg orally three times a day for 7 days





Chancroid — Reported Cases by Year, United States, 1981–2014



2014 Fig 47. SR Pg 45



Infeções por bactérias II



- Uretrite não Gonocócica
  - *Clamidia tracomatis*
    - Bactéria gram negativa
    - Período de incubação: 3 a 30 dias
      - Apresentações clínicas
        - Linfogranuloma venéreo
        - Epididimite
        - Cervicite
        - Salpingite
        - RN (Conjuntivite, Pneumonia)
  - Outros agentes
    - *Mycoplasma genitalium*
      - Bactéria Gram (?)
      - Período de incubação: 1 a 3 semanas
    - *Ureaplasma urealyticum*
      - Bactéria gram negativa
      - Período de incubação: 10 a 20 dias

Recommended Regimen

Doxycycline 100 mg orally twice a day for 21 days

Alternative Regimen

Erythromycin base 500 mg orally four times a day for 21 days



Tratamento da uretrite por *Clamidia Tracomatis*

Recommended Regimens
Azithromycin 1 g orally in a single dose OR **Doxycycline** 100 mg orally twice a day for 7 days
Alternative Regimens
Erythromycin base 500 mg orally four times a day for 7 days OR **Erythromycin ethylsuccinate** 800 mg orally four times a day for 7 days OR **Levofloxacin** 500 mg orally once daily for 7 days OR **Ofloxacin** 300 mg orally twice a day for 7 days

Recommended Regimens
Azithromycin 1 g orally in a single dose
Alternative Regimens
Amoxicillin 500 mg orally three times a day for 7 days OR **Erythromycin** base 500 mg orally four times a day for 7 days OR **Erythromycin** base 250 mg orally four times a day for 14 days OR **Erythromycin ethylsuccinate** 800 mg orally four times a day for 7 days OR **Erythromycin ethylsuccinate** 400 mg orally four times a day for 14 days

Chlamydia — Rates of Reported Cases by Sex, United States, 1994–2014



NOTE: As of January 2000, all 50 states and the District of Columbia have regulations that require the reporting of chlamydia cases.

2014 Fig 1. SR, Pg 8

Mycoplasma Genitalium I





Mycoplasma Genitalium II

M. genitalium & Reproductive Tract Disease

- Definitely associated with NGU in men
- Study of association with:
  - Cervicitis
  - PID
  - Infertility
  - Preterm delivery
- Summary OR = ~2.0 for all conditions
  - Statistically significant for all but infertility

L. Manhart, with permission *Lis et al., unpublished data*

Detecting MG infections?

No FDA-approved diagnostic test

- **Hologic Gen-Probe TMA assay**
  - Research use only

- **Commercial Laboratories & PCR tests**
  - Limited test-performance information

Request A Test

Quest Diagnostics

LabCorp

L. Manhart, with permission

Mycoplasma Genitalium III

MG cure rates with doxycycline and azithromycin

Randomized Trials

Doxycycline (100mg bid x 7d) vs. Azithromycin (1g)



CONCLUSION: AZM (1g) is superior to DOX (100mg bid x 7d). However, efficacy of AZM is not consistently high and may be declining

L. Manhart, with permission

MG Treatment

Moxifloxacin 400mg po x 7-14d

- Highly effective for treatment failures
  - 100% cure rates in most places
- Public health 340b pricing available
  - Usual price for 7 day course ~ $100+
  - Negotiated price to **$1.21/pill**
- ***Caveat:*** Moxifloxacin treatment failures emerging *(Japan, Seattle, Australia)*

L. Manhart, with permission

Infeções por bactérias III

- Uretrite Gonocócica
  - *Neissseria Gonorrea*
    - Diplococo gram negativo
    - Período de incubação: 2 a 7 dias
    - Apresentação clínica
      - Cervicite
      - Proctite
      - Salpingite
      - Faringite
      - Artrite



Gonorrhea — Rates of Reported Cases by Year, United States, 1941–2014



2014-Fig 12. SR, Pg 19

Neisseria gonorrhoeae — Percentage of Isolates with Elevated Ceftriaxone Minimum Inhibitory Concentrations (MICs) (≥0.125 µg/ml), Gonococcal Isolate Surveillance Project (GISP), 2006 – 2014



2014-Fig 26. SR, Pg 26

Neisseria gonorrhoeae — Percentage of Isolates with Elevated Cefixime Minimum Inhibitory Concentrations (MICs) (≥0.25 µg/ml), Gonococcal Isolate Surveillance Project (GISP), 2006 – 2014



*Isolates not tested for cefixime susceptibility in 2007 and 2008.

2014-Fig 27. SR, Pg 26

Neisseria gonorrhoeae — Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs), Gonococcal Isolate Surveillance Project (GISP), 2010–2014



2014-Fig 28. SR, Pg 27

Neisseria gonorrhoeae — Percentage of Isolates, with Penicillin, Tetracycline, and/or Ciprofloxacin Resistance, Gonococcal Isolate Surveillance Project (GISP), 2014



NOTE: PenR = penicillinase-producing *Neisseria gonorrhoeae* and chromosomally-mediated penicillin-resistant *N. gonorrhoeae*; TetR = chromosomally- and plasmid-mediated tetracycline-resistant *N. gonorrhoeae*; and QRNG = quinolone-resistant *N. gonorrhoeae*.

2014-Fig 29. SR, Pg 27

Tratamento da uretrite por *Neisseria Gonorrea*

Recommended Regimen
Ceftriaxone 250 mg IM in a single dose PLUS **Azithromycin** 1g orally in a single dose



Alternative Regimens
If ceftriaxone is not available: **Cefixime** 400 mg orally in a single dose PLUS **Azithromycin** 1 g orally in a single dose

Epidemiologia da uretrite nos EUA

Some Groups Bear a Disproportionate Burden of STDs

While anyone can become infected with an STD, certain groups, including young people and gay and bisexual men, are at greatest risk.

Gonorrhea and chlamydia primarily affect young people

Surveillance data shows both the numbers and rates of reported cases of chlamydia and gonorrhea continues to be highest among young people aged 15-24.

Both young men and young women are heavily affected by STDs — but young women face the most serious long-term health consequences. It is estimated that undiagnosed STDs cause more than 20,000 women to become infertile each year.

Most Reported Chlamydia and Gonorrhea Infections Occur among 15–24-Year-Olds



Percentages may not add to 100 because ages were unknown for a small number of cases.

Pelvic Inflammatory Disease — Initial Visits to Physicians' Offices by Among Women Aged 15–44 Years, United States, 2004–2013



NOTE: The relative standard errors for these estimates are 16%–23%.

SOURCE: National Disease and Therapeutic Index, IMS Health, Integrated Promotional Services™, IMS Health Report, 2004–2013. The 2014 data were not obtained in time to include them in this report.

2014-Fig E. SR Pg 58.

Pelvic Inflammatory Disease (PID)

- 10%-20% women with GC develop PID
- In Europe and North America, higher proportion of *C. trachomatis* than *N. gonorrhoeae* in women with symptoms of PID
- CDC minimal criteria
  - Uterine tenderness, adnexal tenderness +/- cervical motion tenderness
- Other symptoms include
  - endocervical discharge, fever, lower abdominal pain
- Complications:
  - Infertility: 15%-24% with 1 episode PID secondary to gonorrhea or chlamydia
  - 7X risk of ectopic pregnancy with 1 episode PID
  - chronic pelvic pain in 18%

Pelvic Inflammatory Disease



Ectopic Pregnancy — Rates Among Commercially Insured Pregnant Women Aged 15–44 Years by Age, 2003–2013



SOURCE: MarketScan Commercial Claims and Encounters Database, Truven Health Analytics, Ann Arbor, MI, 2003-2013.

2014-Fig G. SR Pg 59

Tratamento da Doença Inflamatória Pélvica

Recommended Parenteral Regimens

Cefotetan 2 g IV every 12 hours
PLUS
Doxycycline 100 mg orally or IV every 12 hours
OR
Cefoxitin 2 g IV every 6 hours
PLUS
Doxycycline 100 mg orally or IV every 12 hours
OR
Clindamycin 900 mg IV every 8 hours
PLUS
Gentamicin loading dose IV or IM (2 mg/kg), followed by a maintenance dose (1.5 mg/kg) every 8 hours. Single daily dosing (3–5 mg/kg) can be substituted.

Alternative Parenteral Regimen

Ampicillin/Sulbactam 3 g IV every 6 hours
PLUS
Doxycycline 100 mg orally or IV every 12 hours

Recommended Intramuscular/Oral Regimens

Ceftriaxone 250 mg IM in a single dose
PLUS
Doxycycline 100 mg orally twice a day for 14 days
WITH* or WITHOUT
Metronidazole 500 mg orally twice a day for 14 days
OR
Cefoxitin 2 g IM in a single dose and **Probenecid**, 1 g orally administered concurrently in a single dose
PLUS
Doxycycline 100 mg orally twice a day for 14 days
WITH or WITHOUT
Metronidazole 500 mg orally twice a day for 14 days
OR
Other parenteral third-generation **cephalosporin** (e.g., ceftizoxime or cefotaxime)
PLUS
Doxycycline 100 mg orally twice a day for 14 days
WITH* or WITHOUT
Metronidazole 500 mg orally twice a day for 14 days

* The recommended third-generation cephalsporins are limited in the coverage of anaerobes. Therefore, until it is known that extended anaerobic coverage is not important for treatment of acute PID, the addition of metronidazole to treatment regimens with third-generation cephalosporins should be considered (**Source:** Walker CK, Wiesenfeld HC. Antibiotic therapy for acute pelvic inflammatory disease: the 2006 CDC Sexually Transmitted Diseases Treatment Guidelines. Clin Infect Dis 2007;28[Supp 1]:S29–36).

Infeções por bactérias III: *Treponema Palidum* (Sífilis)

- Bactéria gram negativa espiralada
- Período de incubação: 10 a 90 dias
- Formas clínicas
  - Primária (PI: 1 semana – 3 meses)
  - Secundária (2 – 8 semanas depois)
  - Terciária (meses – anos depois)
    - SNC
    - Cardio-Vascular
  - Congénita









Syphilis — Reported Cases by Stage of Infection, United States, 1941–2014



2014-Fig 31, SR, Pg 33

Congenital Syphilis — Reported Cases by Year of Birth and Rates of Primary and Secondary Syphilis Among Women, United States, 2005–2014



* CS=congenital syphilis; P&S=primary and secondary syphilis.

2013-Fig 45, SR Pg 39

Troubling rise in syphilis infections among men, particularly gay and bisexual men

Gay and Bisexual Men Face Highest – and Rising – Number of Syphilis Infections



† Men who have Sex with Men †† Men who have Sex with Women

Note: Based on available data from states reporting sex of sex partners

Tratamento da Sífilis

Recommended Regimen for Adults*

Benzathine penicillin G 2.4 million units IM in a single dose

* Recommendations for treating syphilis in persons with HIV infection and pregnant women are discussed elsewhere in this report (see Syphilis among Persons with HIV infection and Syphilis during Pregnancy).

Recommended Regimens for Adults*

Early Latent Syphilis
Benzathine penicillin G 2.4 million units IM in a single dose

Late Latent Syphilis or Latent Syphilis of Unknown Duration
Benzathine penicillin G 7.2 million units total, administered as 3 doses of 2.4 million units IM each at 1-week intervals

* Recommendations for treating syphilis in persons with HIV infection and pregnant women are discussed elsewhere in this report (see Syphilis in Persons with HIV infection and Syphilis during Pregnancy).

Recommended Regimen

Tertiary Syphilis with Normal CSF Examination
Benzathine penicillin G 7.2 million units total, administered as 3 doses of 2.4 million units IM each at 1-week intervals

Recommended Regimen

Neurosyphilis and Ocular Syphilis
Aqueous crystalline penicillin G 18–24 million units per day, administered as 3–4 million units IV every 4 hours or continuous infusion, for 10–14 days



Infeções por bactérias IV: *Klebsiella granulomatis* (Granuloma Inguinal- Donovanose)

- Bacilo gram negativo
- Período de incubação: 7 a 30 dias
- Endémica: África, Ásia e América do Sul

Recommended Regimen
Azithromycin 1 g orally once per week or 500 mg daily for at least 3 weeks and until all lesions have completely healed
Alternative Regimens
Doxycycline 100 mg orally twice a day for at least 3 weeks and until all lesions have completely healed OR **Ciprofloxacin** 750 mg orally twice a day for at least 3 weeks and until all lesions have completely healed OR **Erythromycin** base 500 mg orally four times a day for at least 3 weeks and until all lesions have completely healed OR **Trimethoprim-sulfamethoxazole** one double-strength (160 mg/800 mg) tablet orally twice a day for at least 3 weeks and until all lesions have completely healed





Infeções Virais I: HPV (DNA)

HPV

- Transmission: skin-to-skin contact
- High-risk (16, 18 etc) vs low-risk (6, 11 etc) types
  - Low-risk types: genital warts
  - High-risk HPV infection is causally associated with cervical cancer and other anogenital squamous cell cancers (e.g. anal, penile, vulvar, vaginal)
- Diagnosis: Clinical exam, cytology, nucleic acid amplification methods (in conjunction with cytology for high-risk HPV types)
- Treatment: Topical and destructive modalities









Human Papillomavirus — Cervicovaginal Prevalence of Types 6, 11, 16 and 18 Among Women Aged 14–59 Years by Age Group and Time Period, National Health and Nutrition Examination Survey, 2003–2006 and 2007–2010



NOTE: Error bars indicate 95% confidence interval.
SOURCE: Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010. J Infect Dis 2013;208(3):385–93.

2014 Fig 49. SR Pg 46

Genital Warts—Initial Visits to Physicians' Offices, United States, 1966–2013



NOTE: The relative standard errors for genital warts estimates of more than 100,000 range from 18% to 23%.
SOURCE: National Disease and Therapeutic Index, IMS Health, Integrated Promotional Services™. IMS Health Report, 1966–2013. The 2014 data were not obtained in time to include them in this report.

2014 Fig 50. SR Pg 46

HPV-Associated Cervical Cancer

- 528,000 cases of cervical cancer in 2012 world-wide
- In US, rates down but still 11,818 cases and 3,939 deaths from cervical cancer in 2010

Anal Cancer Statistics

- New anal cancer cases in U.S. (2013): 7060
- Deaths from anal cancer in U.S. (2013): 880
- 0.4% of all cancers diagnosed in the U.S. in 2013
- Anal Cancer rates have increased by ~2%/yr since the 1970's
- Incidence of SCCA among men in general population (~0.8/100K) vs HIV-infected MSM (~70/100K)

HPV: vírus oncogénico!

HPV: Prevention

- Non-vaccine modalities:
  - Decrease number of partners
  - Condoms
    - 70% reduction in newly sexually active college women when partners consistently used condoms
    - Shown to reduce incident infection, associated with lower rate of cervical cancer and associated with regression of HPV-related cervical and penile lesions
  - Microbicides
  - Treatment of warts
- Smoking cessation

HPV Vaccines - Females

Cervarix™ – GSK

- HPV 16 and 18
- 0, 1, 6mo dosing
- Females 10-25yrs
- Approved 10/09

Giardasil™ - Merck

- HPV types 6,11,16,18
- 0, 2, 6mo dosing
- Females 9-26yrs
- Approved 6/06

Efficacy approximately 100% against precancerous lesions caused by specific types in the vaccine!

Gardasil for Males

- Initial study demonstrated 90+% efficacy for preventing external lesions caused by HPV types 6, 11, 16 and 18 in men 16-26y
- FDA approved (10/09) for males 9-26 for prevention of genital warts

Infeções Virais II (HSV1 / HSV2 DNA):
Terapêutica da fase aguda e supressiva das recorrências

Recommended Regimens*
Acyclovir 400 mg orally three times a day for 7–10 days OR **Acyclovir** 200 mg orally five times a day for 7–10 days OR **Valacyclovir** 1 g orally twice a day for 7–10 days OR **Famciclovir** 250 mg orally three times a day for 7–10 days
* Treatment can be extended if healing is incomplete after 10 days of therapy.

Recommended Regimens
Acyclovir 400 mg orally twice a day OR **Valacyclovir** 500 mg orally once a day* OR **Valacyclovir** 1 g orally once a day OR **Famiciclovir** 250 mg orally twice a day
* Valacyclovir 500 mg once a day might be less effective than other valacyclovir or acyclovir dosing regimens in persons who have very frequent recurrences (i.e., ≥10 episodes per year).







Herpes Simplex 2: Terapêutica pre-emptiva

Recommended regimen for suppressive therapy of pregnant women with recurrent genital herpes *
Acyclovir 400 mg orally three times a day OR **Valacyclovir** 500 mg orally twice a day
* Treatment recommended starting at 36 weeks of gestation. (**Source:** American College of Obstetricians and Gynecologists. Clinical management guidelines for obstetrician-gynecologists. Management of herpes in pregnancy. ACOG Practice Bulletin No. 82. Obstet Gynecol 2007;109:1489–98.)

Recommended Regimens
Acyclovir 400 mg orally three times a day for 5 days OR **Acyclovir** 800 mg orally twice a day for 5 days OR **Acyclovir** 800 mg orally three times a day for 2 days OR **Valacyclovir** 500 mg orally twice a day for 3 days OR **Valacyclovir** 1 g orally once a day for 5 days OR **Famciclovir** 125 mg orally twice daily for 5 days OR **Famciclovir** 1 gram orally twice daily for 1 day OR **Famciclovir** 500 mg once, followed by 250 mg twice daily for 2 days

Genital Herpes—Initial Visits to Physicians' Offices, United States, 1966–2013



NOTE: The relative standard errors for genital herpes estimates of more than 100,000 range from 19% to 23%.
SOURCE: National Disease and Therapeutic Index, IMS Health, Integrated Promotional Services™. IMS Health Report, 1966–2013. The 2014 data were not obtained in time to include them in this report.

2014-Fig 53. SR Pg 48

Infeções Virais III: Hepatite A (RNA)

- Período de incubação: 15 – 50 dias
- Mortalidade da infeção aguda em adultos: 0,5 - 3% (> 50 anos)
- Transmissão sexual
  - Sexo anal
- Vacinação
  - Viagens
  - Imunodeprimidos (HIV, etc.)
  - Hepatite crónica p/ HBV/HCV
  - Comportamentos de risco (MSM)





Infeções Virais IV: **Hepatite B (DNA)**





- Período de incubação: 60 – 150 dias
- Mortalidade: 1% (após a infeção aguda)
- Evolução para a cronicidade
  - R/N: 90%
  - Crianças: 25 – 50 %
  - Adultos: 2 – 6%
- Vacinação
  - Plano vacinal nacional (infância)
  - Viagens
  - Imunodeprimidos (HIV, etc.)
  - Hepatite crónica p/ HCV
  - Comportamentos de risco (IVDU; MSM)

Infeções Virais V: **Hepatite C (RNA)**

- **Transmissão vertical: até 6%**
- **Transmissão sexual: reduzida (c/ exceções)**
- **Período de incubação: 2 semanas – 6 meses**





MAJOR ARTICLE HIV/AIDS

Unsafe Sex and Increased Incidence of Hepatitis C Virus Infection among HIV-Infected Men Who Have Sex with Men: The Swiss HIV Cohort Study

Andri Rauch,[1] Martin Rickenbach,[2] Rainer Weber,[3] Bernard Hirschel,[4] Philip E. Tarr,[5] Heiner C. Bucher,[6] Pietro Vernazza,[7] Enos Bernasconi,[8] Annelies S. Zinkernagel,[3] John Evison,[1] and Hansjakob Furrer,[1] and the Swiss HIV Cohort Study[a]

[1]Division of Infectious Diseases, University Hospital Berne, [2]Data Center Swiss HIV Cohort Study, Lausanne, [3]Division of Infectious Diseases, University Hospital Zurich, [4]Division of Infectious Diseases, University Hospital Geneva, [5]Division of Infectious Diseases, University Hospital Lausanne, [6]Basel Institute for Clinical Epidemiology, University Hospital Basel, [7]Division of Infectious Diseases, Kantonsspital St. Gallen, and [8]Division of Infectious Diseases, Ospedale Civico Lugano, Switzerland

Background. Data on the incidence of hepatitis C virus (HCV) infection among human immunodeficiency virus (HIV)–infected persons are sparse. It is controversial whether and how frequently HCV is transmitted by unprotected sexual intercourse.

Methods. We assessed the HCV seroprevalence and incidence of HCV infection in the Swiss HIV Cohort Study between 1988 and 2004. We investigated the association of HCV seroconversion with mode of HIV acquisition, sex, injection drug use (IDU), and constancy of condom use. Data on condom use or unsafe sexual behavior were prospectively collected between 2000 and 2004.

Results. The overall seroprevalence of HCV infection was 33% among a total of 7899 eligible participants and 90% among persons reporting IDU. We observed 104 HCV seroconversions among 3327 participants during a total follow-up time of 16,305 person-years, corresponding to an incidence of 0.64 cases per 100 person-years. The incidence among participants with a history of IDU was 7.4 cases per 100 person-years, compared with 0.23 cases per 100 person-years in patients without such a history ($P < .001$). In men who had sex with men (MSM) without a history of IDU who reported unsafe sex, the incidence was 0.7 cases per 100 person-years, compared with 0.2 cases per 100 person-years in those not reporting unsafe sex ($P = .02$), corresponding to an incidence rate ratio of 3.5 (95% confidence interval, 1.2–10.0). The hazard of acquiring HCV infection was elevated among younger participants who were MSM.

Conclusions. HCV infection incidence in the Swiss HIV Cohort Study was mainly associated with IDU. In HIV-infected MSM, HCV infection was associated with unsafe sex.

HCV: História natural



As novas terapêuticas da Hepatite C!



HIV (RNA)






Primary infection
±Acute HIV syndrome
Wide dissemination of virus
Seeding of lymphoid organs
Clinical latency
Constitutional symptoms
Opportunistic diseases
Death
CD4+ T Lymphocyte Count (cells/mm³)
Culturable Plasma Viremia (dilutional titer)
Weeks
Years
Symptoms
p24 Antigen
HIV-1 RNA
HIV Ab Tests
Weeks Since Infection
Ab, antibody.

HIV: Atitudes / Situações de Risco

- Epidemiology: Risk of HIV Infection after single exposure
  - Transfusion of HIV positive blood: >90%
    - U.S. Risk: less than 1 per 100.000 transfusions are HIV contaminated
  - Percutaneous needle stick: 0.3%
  - Receptive anal intercourse: 0.5%
  - Receptive vaginal intercourse: 0.1%
  - Insertive intercourse: 0.05 to 0.07%
  - Oral intercourse: 0.005 to 0.01%
  - Blood to mucous membrane: 0.09%
  - Blood to non-intact skin: <0.1%
  - Maternal to fetal vertical transmission
    - 25-30% (s/ TARV)
    - 1-2% (c/ TARV)

HIV: Epidemiologia mundial





HIV: Dinâmica epidemiológica mundial



HIV: Epidemiologia em Portugal I

FIGURA 1 **DISTRIBUIÇÃO DOS CASOS DE INFEÇÃO POR VIH, POR ANO DE DIAGNÓSTICO E POR CATEGORIA DE TRANSMISSÃO, EM PORTUGAL (2004-2014)**



Fonte: Elaborado por PN VIH/SIDA com base em dados do INSA (DDI-URVE) e SI.VIDA (recolhidos em 31.08.2015)

HIV: Epidemiologia em Portugal II

3. MORTALIDADE

FIGURA 2 PERCENTAGEM DE ÓBITOS PELAS PRINCIPAIS CAUSAS DE MORTE NO TOTAL DAS CAUSAS DE MORTE EM PORTUGAL (1988-2013)



Fonte: INE, IP 2015

HIV: Epidemiologia em Portugal III

FIGURA 3 ANOS POTENCIAIS DE VIDA PERDIDOS POR CAUSAS DE MORTE SELECIONADAS, EM PORTUGAL (2013)



Fonte: Elaborado por DGS com base nos dados do INE, IP 2015

HIV: Epidemiologia Molecular

Figure 1 Regional HIV-1 subtype and circulating recombinant form (CRF) distribution



Modified and updated from Hemelaar *et al.* [6]. 03_AB = CRF03_AB; 12_BF = CRF12_BF; 01_AE = CRF01_AE; 07_BC = CRF07_BC; 08_BC = CRF08_BC; RF = unique recombinant form.

HIV: Apresentação Tardia da Infeção







Primoinfeção: Critérios

■ TABLE 1-2: **Primary HIV Infection: Signs and Symptoms (Department of Health and Human Services [DHHS] Guidelines [*Ann Intern Med* 2002;137:381])**

Fever – 96%	Myalgias – 54%	Hepatosplenomegaly – 14%
Adenopathy – 74%	Diarrhea – 32%	Weight loss – 13%
Pharyngitis – 70%	Headache – 32%	Thrush – 12%
Rash* – 70%	Nausea & vomiting – 27%	Neurologic symptoms† – 12%

Primoinfecção: RASH



Dermatose Seborreica









Fuliculite









Herpes Zoster









Psoríase





Candidose oral



Tricoleucoplasia da Língua









Molusco Contagioso



Ulcerações (Aftas)



PTI (Trombocitopénia)



Pneumonia da Comunidade



Sarcoma de Kaposi Cutâneo - Mucoso









Complicações oportunistas



Anti-Retrovíricos I: *"Timeline"*



Anti-Retrovíricos II: Mecanismos de ação



Anti-Retrovíricos III: Formas de apresentação aprovadas

Antiretroviral drugs 2015/16 — www.i-Base.info

Phoneline 0808 800 6013 — Monday–Wednesday 12 noon–4pm

Drug names		Recommended adult dose *	Total daily pills
Fixed dose combinations §			
Atripla (efavirenz 600 mg + emtricitabine 200 mg + tenofovir DF 300 mg)		One tablet, once-daily. Take at night and not with a high fat meal. See info on separate drugs.	1
Eviplera (rilpivirine 25 mg + emtricitabine 200 mg + tenofovir DF 300 mg)		One tablet, once-daily, with food (390 kcal). See separate drug info.	1
Stribild (elvitegravir 150 mg + cobicistat 150 mg + emtricitabine 200 mg + tenofovir DF 300 mg)		One tablet, once-daily, take with food. See info on separate drugs.	1
Triumeq (dolutegravir 50 mg + abacavir 600 mg + lamivudine 300 mg)		One tablet, once-daily. Take with or without food. See info on separate drugs.	1
Nukes: nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs)			
Dual nukes			
Truvada (tenofovir DF 300 mg + emtricitabine 200 mg)		One tablet, once-daily.	1
Kivexa (abacavir 600 mg + lamivudine 300 mg)		One tablet, once-daily.	1
Single nukes			
lamivudine (3TC) ++ (Epivir [pictured] - or generic)		1 x 300 mg or 2 x 150 mg (150 mg shown), (taken as a once-daily or twice-daily dose).	1 if 300 mg 2 if 150 mg
abacavir (Ziagen)		2 x 300 mg tablets (taken as a once-daily or twice-daily dose).	2
emtricitabine (FTC) (Emtriva)		1 x 200 mg capsule, once-daily.	1
tenofovir DF (Viread)		1 x 300 mg tablet, once-daily.	1

§ New fixed dose combinations and coformulations might become available during 2015/16.
* Different doses and formulations are sometimes used - always check the dose with your doctor and pharmacist.
++ Generic versions of lamivudine, nevirapine and efavirenz may be a different colour and shape.
°° Elvitegravir is only available as a separate drug on expanded access from the manufacturer.
∞ PK boosters: ritonavir is the most widely used pharmacokinetic (PK) booster. Cobicistat can only be used to boost atazanavir, darunavir and elvitegravir.

Some drugs are not recommended for first-line therapy. Smaller pills are for children or if larger pills are difficult to swallow. Some syrups are available. Pictures approximate to actual size.

Drug names		Recommended adult dose *	Total daily pills
NNRTIs: non-nucleoside reverse transcriptase inhibitors (non-nukes)			
efavirenz ++ (Sustiva) 600 mg or 200 mg		1 x 600 tablet (or 3 x 200 caps) once-daily; at night, not with high fat meal.	1 tablet (or 3 capsules)
nevirapine ++ 200 mg and nevirapine 400 mg (Viramune PR)		200 mg once-daily for first 14 days. Then 1 x 200 mg tablet, twice-daily or 2 x 200 mg once-daily; OR 1 x 400 mg prolonged release tablet once-daily (pic on right).	1 or 2 (based on 200 mg or 400 mg)
etravirine (Intelence)		1 x 200 mg tablet, twice daily, take with food. Dispersible in water.	2
rilpivirine § (Edurant)		1 x 25 mg tablet, once-daily, take with main meal (500 kcal).	1
INIs: integrase inhibitors			
raltegravir (Isentress)		1 x 400 mg tablet, twice-daily. Take with or without food.	2
elvitegravir (Vitekta) °° (see also Stribild). Named patient access only.		1 x 85 mg or 1 x 150 mg tablet, once-daily in boosted PI. Take with food.	1 (+ 1 booster)
dolutegravir (Tivicay) *		1 x 50 mg tablet, once-daily (or 1 x 50 mg twice -daily). With food if twice-daily but with or without otherwise.	1 or 2
CCR5 inhibitors (entry inhibitor)			
maraviroc * (Celsentri)		150 mg or 300 mg or 600 mg, as directed, depending on other ARVs in the combination.	1 or 2 or 4
b/PI: boosted protease inhibitors			
atazanavir * § (Reyataz)		1 x 300 mg cap + booster, once-daily. Take with food. 150 mg and 200 mg capsules also available.	1 (+ 1 booster)
darunavir * § (Prezista)		1 x 800 mg + booster once-daily (or 1 x 600 mg + 100 mg booster twice-daily if resistance). Take with food.	1 or 2 (+ 1 or 2 boosters based on dose)
PK (pharmacokinetic) boosters ∞			
cobicistat (/c) § (Tybost)		150 mg tablet, once daily. Used to boost atazanavir, darunavir and elvitegravir.	depends on boosted drug
ritonavir (/r) * (Norvir)		100 mg tablets used at different doses to boost other PIs.	depends on PI

REVIEW

Travel and Sexually Transmitted Infections

Brian J. Ward, MDCM, * and Pierre Plourde, MD†

*McGill University Tropical Diseases Centre, Montreal General Hospital, Montreal, Quebec, Canada; †Population and Public Health Program, Winnipeg Regional Health Authority, Winnipeg, Manitoba, Canada



ESTILOS DE VIDA

BAREBACK



Dá-me a tua SIDA

Com o aparecimento do Sindroma de Insuficiência Imunitária (HIV/SIDA), a forma de encarar a sexualidade sofreu uma mudança profunda e despertou novas preocupações e apreensões na mentalidade humana. Com o aumento dos inúmeros casos de seropositivos na década de 80/90, e o alarmante número de mortes registado devido ao HIV, os efeitos traduziram-se em extensas campanhas de prevenção de forma a consciencializar a sociedade para a necessidade de comportamentos sexuais seguros e para a urgência de pôr um freio na proliferação da doença.

No entanto, as décadas de luta e sofrimento e a perda de inúmeras vidas humanas, vítimas de um dos mais temidos flagelos conhecidos pelo Homem, está a sofrer um revés nas suas pretensões de irradiar (ou pelo menos diminuir) novos casos de Sindroma de Insuficiência Imunitária a nível global... E esse revés tem nome... Bareback!

ESTILOS DE VIDA

- **Barebacking Party's**
  Festas de sexo em grupo sem uso de preservativo
- **The Gift**
  (o presente)
  O HIV
- **Gift Givers**
  (doadores de presentes)
  Individuo HIV positivo que contamina HIV negativo
- **Bug Chasers**
  (caçadores de vírus)
  HIV- procurando receber o vírus da SIDA
- **Conversion Party's**
  (festas de conversão)
  Festas onde os bug chasers são convertidos em Gift Givers
- **Fuck of Death**
  (foda da morte)
  Sexo quando é transmitido o HIV
- **Bug Brothers**
  (irmãos de problemas)
  Grupo de indivíduos HIV+
- **Charged Cum/Poz Cum**
  (ejaculação carregada)
  Sémen com HIV

ÁFRICA QUE MORRE

As cores do VIH

Cem dólares pagam o tratamento, durante um ano. Mas não as estradas, os hospitais ou os enfermeiros necessários para tratar os 4 milhões e 600 mil seropositivos que vivem em África...

POR **SARA SÁ** TEXTO **ANTONIN KRATOCHVIL/VII** FOTOS



Silvia Ng'andwe, 27 anos, da Zâmbia, no final de Março de 2007, e no princípio de Maio, 40 dias depois de ter começado a tomar anti-retrovirais



HIV / HBV / HCV: Pandemias Coincidentes



Les tribulations
de la peste bubonique

Colin McEVEDY

Pendant plus de 2 000 ans, cette maladie bactérienne, véhiculée par les puces des rats, a décimé l'espèce humaine. Des témoignages historiques permettent de reconstituer le chemin de ce fléau.



2. **La Grande Peste** emportait les riches comme les pauvres, comme le montre cette enluminure du XVe siècle, au frontispice du Décaméron, œuvre écrite par Boccace après l'épidémie qui toucha Florence.



4. **La peste noire** vint d'Asie centrale et atteignit l'Europe par la route de la soie ; on signala une épidémie à Saraï en 1346 et, de Kaffa, qu'elle atteignit vers 1347, elle fut véhiculée par bateau vers les grands ports de l'Europe et de l'Afrique du Nord. La plus grande partie de l'Europe fut touchée, avant que l'épidémie ne cesse enfin en 1352.

A Peste Bubónica no Porto




Luís da **Câmara Pestana** fundou e dirigiu o Instituto Bacteriológico (1892) que receberia o seu nome.
Óleo de João Galhardo, 1900





Infeções por parasitas I: *Tricomas vaginalis* (Protozoário)



Recommended Regimen
Metronidazole 2 g orally in a single dose OR **Tinidazole** 2 g orally in a single dose
Alternative Regimen
Metronidazole 500 mg orally twice a day for 7 days

Recommended Regimen for Women with HIV Infection
Metronidazole 500 mg orally twice daily for 7 days

Trichomoniasis and Other Vaginal Infections Among Women—Initial Visits to Physicians' Offices, United States, 1966–2013



NOTE: The relative standard errors for trichomoniasis estimates range from 16% to 21% and for other vaginitis estimates range from 8% to 13%.

SOURCE: National Disease and Therapeutic Index, IMS Health, Integrated Promotional Services™, IMS Health Report, 1966–2013. The 2014 data were not obtained in time to include them in this report.

Infeções por parasitas II: Pediculose (ectoparasita)

Recommended Regimens
Permethrin 1% cream rinse applied to affected areas and washed off after 10 minutes OR **Pyrethrins with piperonyl butoxide** applied to the affected area and washed off after 10 minutes
Alternative Regimens
Malathion 0.5% lotion applied to affected areas and washed off after 8–12 hours OR **Ivermectin** 250 μg/kg repeated in 2 weeks

Infeções por parasitas III: Sarna (ectoparasita)



Recommended Regimens

Permethrin 5% cream applied to all areas of the body from the neck down and washed off after 8–14 hours*

OR

Ivermectin 200ug/kg orally, repeated in 2 weeks†

* Infants and young children should be treated with permethrin.

† Infants and young children aged <10 years should not be treated with lindane.

Alternative Regimens

Lindane (1%) 1 oz of lotion or 30 g of cream applied in a thin layer to all areas of the body from the neck down and thoroughly washed off after 8 hours

Infeção por Fungos: *Candida albicans*

Uncomplicated VVC

- Sporadic or infrequent VVC
  AND
- Mild-to-moderate VVC
  AND
- Likely to be *Candida albicans*
  AND
- Nonimmunocompromised women

Complicated VVC

- Recurrent VVC
  OR
- Severe VVC
  OR
- Nonalbicans candidiasis
  OR
- Women with diabetes, immunocompromising conditions (e.g., HIV infection), debilitation, or immunosuppressive therapy (e.g., corticosteroids)

Abbreviation: HIV = human immunodeficiency virus; VVC = vulvovaginal candidiasis.







Recommended Regimens

Over-the-Counter Intravaginal Agents:

Clotrimazole 1% cream 5 g intravaginally daily for 7–14 days
OR
Clotrimazole 2% cream 5 g intravaginally daily for 3 days
OR
Miconazole 2% cream 5 g intravaginally daily for 7 days
OR
Miconazole 4% cream 5 g intravaginally daily for 3 days
OR
Miconazole 100 mg vaginal suppository, one suppository daily for 7 days
OR
Miconazole 200 mg vaginal suppository, one suppository for 3 days
OR
Miconazole 1,200 mg vaginal suppository, one suppository for 1 day
OR
Tioconazole 6.5% ointment 5 g intravaginally in a single application

Prescription Intravaginal Agents:

Butoconazole 2% cream (single dose bioadhesive product), 5 g intravaginally in a single application
OR
Terconazole 0.4% cream 5 g intravaginally daily for 7 days
OR
Terconazole 0.8% cream 5 g intravaginally daily for 3 days
OR
Terconazole 80 mg vaginal suppository, one suppository daily for 3 days

Oral Agent:

Fluconazole 150 mg orally in a single dose

III)- “Novas” Realidades





Outros vírus…

Ciberbulling!

O cibersexo



Recommended Regimens

Ceftriaxone 250 mg IM in a single dose
PLUS
Azithromycin 1 g orally in a single dose
PLUS
Metronidazole 2 g orally in a single dose
OR
Tinidazole 2 g orally in a single dose



Medidas de emergência

- Considerar
  - Contraceção de emergência
  - HBV (Igb; Vacina)
  - HPV (Vacina)

EMERGENCY CONTRACEPTION



IV)- Mensagens Finais





Grupos de Risco, Situações de Risco e Categorias de Transmissão



Informação, Formação e Alteração dos Comportamentos



A Infecção não se diagnostica pela aparência de cada um …!

Ninguém pode ter a certeza de não estar infectado sem efectuar primeiramente o teste serológico

O Amor e a Paixão não protegem do Contágio



A melhor protecção é a adopção permanente de práticas seguras



Pensar que as más notícias só chegam aos outros é uma atitude fundada na mais profunda ignorância da crua realidade





Investir (bem) agora …

EDUCAÇÃO. ALUNOS FAZEM SEXO NAS CASAS DE BANHO

APANHADOS NA ESCOLA

O convite parte dela e não pode ser mais explícito: "Amor, vamos para a casa de banho?" Entusiasmado, o miúdo responde que sim, claro, e trancam-se nos sanitários da Escola António Arroio, em Lisboa, mesmo à frente da escadaria do segundo andar. Aí não há discriminação por sexos: tanto entram rapazes como raparigas (e às vezes esquecem-se de fechar a porta); as paredes estão cobertas de grafitis de cores garridas; e há mensagens de forte carga sexual. Também Sara deixa o seu contributo na parede. "Dei aqui uma queca três vezes", escreve com uma esferográfica, depois da aventura sexual com o namorado, quando tinham ambos 16 anos. "É o sítio reservado, onde podemos estar mais à vontade", explica ela, habituada às brincadeiras proibidas na escola. Sem casa disponível, nem dinheiro para ir a uma pensão, Sara só via saída no liceu. "Sempre é gratuito", ri-se. E se é certo que tinha receio de ser apanha grante, o desejo sobrepunha o resto. "Dava uma vontade.. deixava de ser importante."

Sara corre riscos e tem noçã mas também sabe que é difíci gada. "Ninguém foi apanhad be-se porquê: para 1300 alun António Arroio, entre os 16 e o só há 20 vigilantes a funcion nos – número reduzido para o que se passa nas dez casas muitas delas em sítios deser exigia que os vigilantes estiv permanência nos sanitários, o possível. Não temos recursos suficientes", diz à SÁBADO a dente do conselho directivo Benedita Salema, embora de comportamentos sexuais n "Não há indícios de que isso te tecido, nem recebemos queix

As estatísticas contrariam a professores. Em média, 11 em

… ou pagar (mais) depois!





Algumas lições da História… nem só no Kamasutra…





… também na Roma Antiga …



… e ainda na “puritana” idade média e no seio dos locais de culto da Santa Igreja Católica!!!



A incompreensão da sociedade perante os portadores de DTSs: O caso da sífilis



Um Doente

- “… quem me infetou? Quantos terei eu infetado? Esta dúvida dilacerante, esta culpabilização doentia que só a racionalidade permite atenuar, persegue-me no dia a dia … o sexo não era um fim em si! Não era a meta pela qual lutávamos! Mas era apenas uma fase dessa comunhão, dessa partilha libertadora, que nos separasse da mediocridade de uma vida espartilhada por lucros feitos ou a fazer … após uma fase de descrédito, seguiu-se a fase de interiorização, com longas noites de insónia, o vasculhar milimétrico do passado, a análise de todas as possibilidades e, o retorno de mãos vazias à realidade, a ignorância e a ilibação de um comportamento também inocente, de alguém que funcionou como elo de transmissão inconsciente …”

- “… o tempo, uma nova noção de tempo, em que a precariedade leva a valorizar em extremo cada momento, e a descoberta de mil pequenos detalhes, outrora perdidos no turbilhão sensorial … como viver com a permanente mentira que resulta da abjeta condição a que são relegados os que, como eu, fizeram da heterodoxia o seu modo de vida … como tranquilizar o condenado a uma morte a prazo, a quem é negado um futuro, prisioneiro do presente e em permanente auto-reflexão sobre o passado …” (sic.)

Hoje, como ontem e SEMPRE!